Properties of a Chlamydia psittaci isolated from muskrats and snowshoe hares in Canada.
D000818:Animals; D000906:Antibodies / Q000032:analysis; D002170:Canada; D002642:Chick Embryo; D002645:Chickens; D002689:Chlamydia / Q000187:drug effects / Q000254:growth & development / Q000276:immunology / Q000302:isolation & purification / Q000472:pathogenicity; D002690:Chlamydia Infections / Q000276:immunology / Q000382:microbiology* / Q000401:mortality / Q000473:pathology / Q000662:veterinary; D006224:Cricetinae; D003523:Cycloserine / Q000494:pharmacology; D004352:Drug Resistance, Microbial; D004372:Ducks; D006168:Guinea Pigs; D007109:Immunity; D002479:Inclusion Bodies; D007612:Kanamycin / Q000494:pharmacology; D051379:Mice; D009500:Neutralization Tests; D011563:Psittaciformes; D011817:Rabbits; D012376:Rodent Diseases / Q000382:microbiology*; D012377:Rodentia; D013307:Streptomycin / Q000494:pharmacology; D013411:Sulfadiazine / Q000494:pharmacology; D014774:Virulence
D000906:Antibodies; D013411:Sulfadiazine; D007612:Kanamycin; D003523:Cycloserine; D013307:Streptomycin